05/30/23 8:30 AMNasdaq : SABS, SABSW conferencesSAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International ConventionSAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stageRHEA-AIpositive
05/19/23 8:30 AMNasdaq : SABS, SABSW SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy InnovationsSAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonalRHEA-AIneutral
05/16/23 8:30 AMNasdaq : SABS, SABSW earningsSAB Biotherapeutics Provides Company Update for Q1 2023 Financial ResultsSAB Biotherapeutics ( Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-humanRHEA-AIneutral
05/12/23 8:30 AMNasdaq : SABS, SABSW clinical trialSAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal AntibodiesIn study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis infection, which causes plague Findings demonstrate utility of Transchromosomic (Tc) bovine generated fully-human immunoglobulin (or polyclonal) antibodiesRHEA-AIneutral
05/09/23 8:30 AMNasdaq : SABS, SABSW SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform- FDA has approved five of seven sections in a rolling submission required for a New Animal Drug Application (NADA) for Company’s antibody generating DiversitAb™ platform in Transchromosomic (Tc) Bovine™ - Announcement further solidifies SAB leading position in delivering, fully-humanRHEA-AIpositive
05/04/23 8:30 AMNasdaq : SABS, SABSW clinical trialSAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG ConferenceFirst fully-human multi-epitope binding broadly neutralizing immunoglobulin antibody therapeutic being developed for treatment of high-risk patients demonstrates safety and efficacy in Phase 1 and 2a Trials SAB-176 and oseltamivir combination therapy shows promising results in preclinical studiesRHEA-AIneutral
05/03/23 5:00 PMNasdaq : SABS, SABSW conferencesSAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin IgG1 (polyclonal) antibodiesRHEA-AIpositive
04/26/23 8:30 AMNasdaq : SABS, SABSW clinical trialcovid-19SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe ComplicationsSAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stageRHEA-AIneutral
04/18/23 8:30 AMNasdaq : SABS, SABSW SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy SAB-176 has now received both Breakthrough and Fast Track designations from FDA – signifying its potential to fundamentally improve influenza treatment and prophylaxis Influenza therapeutic now eligible for intensive guidance from FDA for an efficient development program SAB-176 is the firstRHEA-AIpositive
04/13/23 8:30 AMNasdaq : SABS, SABSW SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of InfluenzaFDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody therapeutic intended to prevent or reduce severe outcomes of Type A and Type B influenza infection inRHEA-AIneutral
